Are you Dr. Petrich?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
676 N Saint Clair St
Ste 2100
Chicago, IL 60611Phone+1 312-695-6180Fax+1 312-695-4770
Summary
- Dr. Adam Petrich, MD is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois. He is an Assistant Professor in Medicine-Hematology/Oncology at Northwestern University Medical School.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2008 - 2011
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2005 - 2008
University of Illinois College of MedicineClass of 2005
Certifications & Licensure
IL State Medical License 2011 - 2017
Clinical Trials
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Start of enrollment: 2015 Jun 11
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsPhase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.Olga Frankfurt, Shuo Ma, Leo I. Gordon, Jane N. Winter, Jeanne M. Horowitz
Leukemia & Lymphoma. 2015-02-01 - 38 citationsIbrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation tes...Jennifer A. Regan, Yun Cao, Melanie C. Dispenza, Shuo Ma, Leo I. Gordon
The Journal of Allergy and Clinical Immunology. 2017-09-01 - 22 citationsPhase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.Ajay Major, Justin Kline, Theodore Karrison, Paul A. S. Fishkin, Amy S. Kimball
Haematologica. 2021-07-29
